Trial Profile
Prediction of trastuzumab-related cardiotoxicity by using left atrium enlargement in patients with HER2-positive breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- 03 Apr 2018 New trial record
- 22 Mar 2018 Results published in the Clinical Cardiology